pipeline candidates

Nuvation Bio's Chief Regulatory Officer sold 200,000 shares for $904K but retained 53,000 shares and 700,000 options, suggesting routine profit-taking rather than lost confidence.

Interstitial lung disease market valued at $6B in 2025 expected to grow 8.7% annually through 2036, driven by FDA-approved therapies and emerging pipeline candidates.

Vertex Pharmaceuticals offers profitable gene-editing exposure versus CRISPR's pipeline-dependent model. Casgevy's slow adoption and high costs make Vertex's diversified, profitable business more attractive for risk-averse investors despite lower upside potential.

Vertex Pharmaceuticals outperforms Centessa with profitable cystic fibrosis revenue, successful product launches, and advanced pipeline, offering lower-risk investment profile versus pre-revenue competitor.

Vertex Pharmaceuticals needs 26% annual growth to turn $100K into $1M by 2036, but its maturing cystic fibrosis franchise and competitive pressures make this ambitious target unlikely despite solid fundamentals.